内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

2021 ETA指南：碘基造影剂致甲状腺功能异常的管理

2021-07-15 欧洲甲状腺协会 Eur Thyroid J .2021July;10(4):269–284.

甲状腺功能

2021年7月，欧洲甲状腺协会(ETA)发布了碘基造影剂致甲状腺功能异常的管理指南，鉴于在日常临床实践中大量应用碘基造影剂（ICM）进行影像学检查，临床医生应意识到其诱发甲状腺功能障碍（TD）的可能。

中文标题：

2021 ETA指南：碘基造影剂致甲状腺功能异常的管理

英文标题：

2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction

发布机构：

欧洲甲状腺协会

发布日期：

2021-07-15

简要介绍：

2021年7月，欧洲甲状腺协会(ETA)发布了碘基造影剂致甲状腺功能异常的管理指南，鉴于在日常临床实践中大量应用碘基造影剂（ICM）进行影像学检查，临床医生应意识到其诱发甲状腺功能障碍（TD）的可能。本文主要针对碘基造影剂致甲状腺功能异常的管理提供指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ETA指南：碘基造影剂致甲状腺功能异常的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=c11c51c00215a38d, title=2021 ETA指南：碘基造影剂致甲状腺功能异常的管理, enTitle=2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction, guiderFrom=Eur Thyroid J .2021July;10(4):269–284., authorId=0, author=, summary=2021年7月，欧洲甲状腺协会(ETA)发布了碘基造影剂致甲状腺功能异常的管理指南，鉴于在日常临床实践中大量应用碘基造影剂（ICM）进行影像学检查，临床医生应意识到其诱发甲状腺功能障碍（TD）的可能。, cover=https://img.medsci.cn/2021815/1629013435674_2020535.jpg, journalId=0, articlesId=null, associationId=483, associationName=欧洲甲状腺协会, associationIntro=欧洲甲状腺协会（European Thyroid Association ETA)成立于1965年，此后每年定期举行一次国际甲状腺会议，会员资格等级分为荣誉会员、普通会员、初级会员、团体会员、合作会员、高级会员六类，目前有600余名会员。旨在推动甲状腺学（基础和临床）及甲状腺病学的发展。, copyright=0, guiderPublishedTime=Thu Jul 15 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年7月，欧洲甲状腺协会(ETA)发布了碘基造影剂致甲状腺功能异常的管理指南，鉴于在日常临床实践中大量应用碘基造影剂（ICM）进行影像学检查，临床医生应意识到其诱发甲状腺功能障碍（TD）的可能。本文主要针对碘基造影剂致甲状腺功能异常的管理提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=3311, tagName=甲状腺功能)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=3311, guiderKeyword=甲状腺功能, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3793, appHits=84, showAppHits=0, pcHits=437, showPcHits=3709, likes=0, shares=7, comments=3, approvalStatus=1, publishedTime=Sun Aug 15 16:06:33 CST 2021, publishedTimeString=2021-07-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Aug 15 15:44:01 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 10:15:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ETA指南：碘基造影剂致甲状腺功能异常的管理.pdf)])
2021 ETA指南：碘基造影剂致甲状腺功能异常的管理.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1077519, encodeId=526310e75192d, content=xuexi, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60af2533682, createdName=12508893m36暂无昵称, createdTime=Mon Dec 06 21:45:27 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064284, encodeId=1e3310642846f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Wed Oct 27 09:09:28 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054864, encodeId=b2261054864a5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e175530724, createdName=ms3000001666531337, createdTime=Sun Sep 26 08:50:17 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-12-06 12508893m36暂无昵称

    xuexi

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1077519, encodeId=526310e75192d, content=xuexi, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60af2533682, createdName=12508893m36暂无昵称, createdTime=Mon Dec 06 21:45:27 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064284, encodeId=1e3310642846f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Wed Oct 27 09:09:28 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054864, encodeId=b2261054864a5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e175530724, createdName=ms3000001666531337, createdTime=Sun Sep 26 08:50:17 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-10-27 ms6000000414198546

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1077519, encodeId=526310e75192d, content=xuexi, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60af2533682, createdName=12508893m36暂无昵称, createdTime=Mon Dec 06 21:45:27 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064284, encodeId=1e3310642846f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Wed Oct 27 09:09:28 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054864, encodeId=b2261054864a5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e175530724, createdName=ms3000001666531337, createdTime=Sun Sep 26 08:50:17 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-09-26 ms3000001666531337

    学习

    0

相关指南

2015 ESPE共识指南：先天性甲状腺功能减退症筛查、诊断和管理

欧洲儿科内分泌学会(ESPE,European Society for Paediatric Endocrinology) · 2015-03-16

拓展阅读

2015 ESPE共识指南：先天性甲状腺功能减退症筛查、诊断和管理

欧洲儿科内分泌学会(ESPE,European Society for Paediatric Endocrinology) · 2015-03-16